Accenture ( ACN) shares lost ground in late trading Tuesday after the consulting and outsourcing company reported that a hefty loss provision pulled down its second-quarter profit. Accenture's earnings for the quarter ended Feb. 28 dropped to $69.7 million, or 11 cents a share, from $209.8 million, or 35 cents a share, a year ago. The results included a $450 million pretax provision for future losses related to the company's future deployment of systems for the National Health Service in England. Without the NHS provision, the company would have posted earnings of 38 cents a share. Revenue was $4.49 billion, including reimbursements. Net revenue totaled $4.10 billion. Analysts polled by Thomson First Call were looking for earnings of 35 cents a share and revenue of $4.14 billion. For the third quarter, Accenture said it expects revenue of $4.3 billion to $4.5 billion and net earnings of 45 cents to 47 cents a share. The forecast is roughly in line with analysts' projection for a profit of 46 cents a share and revenue of $4.47 billion. Shares fell $2.06, or 6.7%, to $28.84 in after-hours trading. TD Ameritrade ( AMTD) said it expects to beat its earnings projection for the second quarter, sending shares higher in late trading. The brokerage said earnings for the quarter ending this week should exceed the high end of its forecast of 28 cents a share, thanks to higher-than-expected trading volume, balances and rates on investable assets. Shares rose 78 cents, or 4.1%, to $19.94 after hours. Shares of Seattle Genetics ( SGEN) fell after the biotech company said it plans to sell 7.3 million common shares. Banc of America Securities and CIBC World Markets will act as joint book-running managers for the offering. Also, the company said it will sell 1.12 million shares to investment funds affiliated with Baker Brothers Investments. Shares declined 49 cents, or 8.5%, to $5.25 in after-hours trading.